November 10, 2021 -- InvestorsHub NewsWire -- via pennymillions
--
MarketWatch
PAO Group, Inc. (OTC:
PAOG) may be consolidating at $0.005, but technicals show the
stock gearing up for a move higher as the RSI and MACD indicate
that the stock's pause may be coming to an end. That could mean
that while its 47% share price increase is impressive, investors
may be in store for significantly higher gains in the coming weeks.
The best part of that assumption is that PAOG has the goods to back
up its case for higher share prices.
In fact, over the past three weeks, PAOG has commercialized two
CBD-based nutraceuticals through its distribution partner North
American Cannabis Holdings (OTC Pink: USMJ). Even better, they are
expecting to launch a third. Not only that, on Monday, PAOG said
it's adding bioidentical synthetic CBD to its overall research
initiative.
By doing so, PAOG is tapping into a massive CBD extracted from
hemp market. And as hemp legalization continues to gain national
and global traction, so do the opportunities for its use to develop
novel CBD therapies. The secret has been out for a while. CBD works
and is helping millions of people.
And the more excellent news for PAOG investors is that since
last month the company has put two products on the market with more
on the way. From a revenue-generating perspective, things are
starting to click for PAOG. And the trend is expected to
continue.
Expanding Its CBD Opportunities
Part of its move into the bioidentical CBD research is that it
puts potential CBD pharmaceuticals into its product mix. It also
adds value to its nutraceutical initiatives. But beyond that, PAOG
is showing it can leverage its IP to create shareholder value. Keep
in mind that the pharmaceutical side of the sector can be enormous.
And Jazz Pharmaceuticals' purchase of GW Pharma for $7.2 billion
earlier this year highlighted the power of owning IP.
And PAOG's IP is proving its worth. It led to PAOG announcing
it's on track to introduce a third CBD nutraceutical product by
year-end. That one will follow the launch of its first two CBD
nutraceutical products, RelaxRX CBD, a sleep aid, and RehabRX CBD,
a salve. By the way, the launch was met with strong demand. PAOG
noted a sell-out of its first run, creating the need for a second
round of production. The products are available at
www.USMJ.com.
Indeed, that's excellent news. And revenues should be impressive
too. The better news is that PAOG is putting in place a revenue
stream that could be substantial over time. An initial sell-out is
welcomed news. Now, if PAOG can stock the shelves, revenues have
the potential to soar. An update in Q4 will provide investors the
first glimpse of how this sub-penny stock could transform into an
impressive revenue-generating company with multiple products on the
market.
Perhaps the better news is that PAOG isn't planning to slow
down. They have also entered into agreements with Alkame Holdings
(OTC Pink: ALKM) to develop a CBD-based line of women's health
products. Alkame can deliver packaging and logistical support to
the initiative. There's still more in the pipeline.
As noted, PAOG is also evaluating how to leverage its IP to
create a synthetic CBD. The research is focused on the many common
over-the-counter supplements such as vitamin C and D, which are not
organic compounds but instead synthetically produced in a lab. Even
though they are not derived from natural resources such as fruit,
they are nevertheless bioidentical to the natural compounds. PAOG
is following the same concept.
In fact, they expect to produce Synthetic CBD in the same way.
But, it's important to note that the synthetic CBD has the
potential of being more "pure" by having fewer contaminants from
the extraction process and less presence of other and conflicting
cannabinoids. PAOG highlighted that it will rely on a technique
that provides a more consistent CBD structure. Hence, from several
initiatives, it's all systems go for PAOG.
Better still, they are gaining operating momentum by adding new
pharmaceutical products to their development pipeline in addition
to the ongoing development of its RespRx CBD pharmaceutical for the
treatment of Chronic Obstructive Pulmonary Disease (COPD).
That product, by the way, can be significant, and PAOG said it's
conducting an in-depth review of its current RespRx CBD
pharmaceutical development project with its CRO partner, industry
consultants, and pharmaceutical firms to explore options and
opportunities to accelerate and diversify development
processes.
As part of the in-depth review, PAOG announced it's considering
a partnership opportunity that could accelerate the development of
its RespRx CBD. Notably, that review has helped PAOG identify
derivative opportunities that could instigate the development and
launch of additional pharmaceutical product development projects.
The most excellent news is that PAOG plans to pursue development
programs that have fast-track potential with the chance of a
pharmaceutical product reaching the market before RespRx. Hence,
the remainder of 2021 and 2022 can be a period of transformational
growth for the company.
And these opportunities are targeting a massive and growing CBD
market.
$5.2 Billion CBD Market
In fact, the market is surging as patients migrate away from
narcotics, especially opioids, and instead embrace CBD for its
effectiveness over addictive drugs known to cause severe unintended
side effects. That migration has changed the CBD nutraceuticals
space from relatively obscure only a few years ago to a more than
$5.2 billion market today. Moreover, it's expected to potentially
double over the next five years. Thus, with PAOG bringing products
to market during the industry's initial growth, they have an
excellent opportunity to earn market share ahead of those late to
the game.
Best of all, PAOG has other business interests, including a
potentially significant interest in a hemp business in Texas. But,
as those develop, focusing on its current marketing opportunities
may be best. After all, they are the revenue drivers contributing
to what could be a record-setting Q4.
Rally Into EOY 2021
Thus, it may be time to put on the PAOG rally caps. After all,
PAOG has officially transformed from a development stage company to
a commercialization one. Better yet, it's gone from two
nutraceuticals on the market to having a third in the queue. And if
that wasn't enough, PAOG has set expectations for more products to
follow, putting potentially exponential growth in the crosshairs
for next year.
Indeed, PAOG is now positioned for multiple revenue-generating
wins. Moreover, they have added diversification to mitigate risk on
the production and distribution side by keeping revenues flowing.
And by focusing on new opportunities to leverage the power of its
IP portfolio, an additional revenue source could soon be put into
the mix. Thus, while two October surprises sent share prices
higher, updates so far in November indicate there's plenty more to
come. If so, at current levels, PAOG stock could be quite a
bargain.
Disclaimers: Hawk Point Media LLC is responsible for the
production and distribution of this content. Hawk Point Media is
not operated by a licensed broker, a dealer, or a registered
investment adviser. It should be expressly understood that under no
circumstances does any information published herein represent a
recommendation to buy or sell a security. Our reports/releases are
a commercial advertisement and are for general information purposes
ONLY. We are engaged in the business of marketing and advertising
companies for monetary compensation. Never invest in any stock
featured on our site or emails unless you can afford to lose your
entire investment. The information made available by Hawk Point
Media is not intended to be, nor does it constitute, investment
advice or recommendations. The contributors may buy and sell
securities before and after any particular article, report and
publication. In no event shall Hawk Point Media be liable to any
member, guest or third party for any damages of any kind arising
out of the use of any content or other material published or made
available by Hawk Point Media, including, without limitation, any
investment losses, lost profits, lost opportunity, special,
incidental, indirect, consequential or punitive damages. Past
performance is a poor indicator of future performance. The
information in this video, article, and in its related newsletters,
is not intended to be, nor does it constitute, investment advice or
recommendations. Hawk Point Media strongly urges you conduct a
complete and independent investigation of the respective companies
and consideration of all pertinent risks. Hawk Point Media was
compensated up to four-thousand-dollars by a third-party to
research, prepare, and syndicate written and visual content about
PAO Group, Inc for one-month. Readers are advised to review SEC
periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms
3, 4, 5 Schedule 13D. For some content, Hawk Point Media, its
authors, contributors, or its agents, may be compensated for
preparing research, video graphics, and editorial content. As part
of that content, readers, subscribers, and website viewers, are
expected to read the full disclaimers and financial disclosures as
part of this content.
The Private Securities Litigation Reform Act of 1995
provides investors a safe harbor in regard to forward-looking
statements. Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, goals, assumptions or future events or performance are
not statements of historical fact may be forward looking
statements. Forward looking statements are based on expectations,
estimates, and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause
actual results or events to differ materially from those presently
anticipated. Forward looking statements in this action may be
identified through use of words such as projects, foresee, expects,
will, anticipates, estimates, believes, understands, or that by
statements indicating certain actions & quote; may, could, or
might occur. Understand there is no guarantee past performance will
be indicative of future results.Investing in micro-cap and growth
securities is highly speculative and carries an extremely high
degree of risk. It is possible that an investors investment may be
lost or impaired due to the speculative nature of the companies
profiled.
Source - https://www.marketwatch.com/press-release/pao-group-inc-stock-consolidating-with-47-gains-since-october-technicals-indicate-a-move-higher-after-expanding-cbd-offerings-otc-pink-paog-2021-11-10
Other stocks on the move include
ABML,
RGST and
ZNOG.
SOURCE: pennymillions
PAO (PK) (USOTC:PAOG)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
PAO (PK) (USOTC:PAOG)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
